FDA granted priority review for atezolizumab (MPDL3280A) for the treatment of people with locally advanced or metastatic non-small cell lung cancer whose disease expresses the protein PD-L1, as determined by an FDA-approved test, and who have progressed on or after platinum-containing chemotherapy. “In a study of atezolizumab in people with previously treated advanced lung cancer,...
In this week's episode of The Cancer Letter Podcast, Paul Goldberg, editor and publisher, and Sara Willa Ernst, reporter, go on a trip into the world of federal health policy surrounding psychedelic medicine.
